Quick Answer
Acrivon Therapeutics, Inc. reported R&D Expense of $59.99 million for fiscal year 2025.
Acrivon Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $59.99M | -6.3% |
| 2024 | $63.99M | +39.0% |
| 2023 | $46.02M | +92.2% |
| 2022 | $23.95M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.65M | -27.7% | -15.7% |
| June 30, 2025 | $16.18M | +7.7% | +5.0% |
| March 31, 2025 | $15.41M | +34.4% | -18.3% |
| September 30, 2024 | $18.86M | +83.7% | +25.6% |
| June 30, 2024 | $15.03M | +42.8% | +31.0% |
| March 31, 2024 | $11.47M | +17.6% | +11.7% |
| September 30, 2023 | $10.27M | — | -2.4% |
| June 30, 2023 | $10.52M | — | +7.8% |
- Acrivon Therapeutics, Inc. showed a decrease of -6.3% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Acrivon Therapeutics, Inc.’s r&d expense has grown by 150.5% (from $23.95 million to $59.99 million).
- The most recent figure is from Acrivon Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: